Pfizer/Astra Talks in 3-6 Months Would Not Be Surprise: JPM
2014-06-20 14:21:54.227 GMT
By Sasha Damouni
June 20 (Bloomberg) -- Pfizer/AstraZeneca deal rationale
still seen as “strong” with talks that may resume over next
3-6 months, if Astra is willing to engage w/ Pfizer on a
friendly deal, JPMorgan analyst Chris Schott said in note.
* Schott says PFE may pursue other business development
transactions to achieve greater critical mass in operating
segments
* PFE could look at mid-cap biotech acquisition to build
out its innovative business or a generic/brand generic
acquisition to broaden GEP portfolio
* JPM added sees a Valeant-Allergan combination as
“incrementally” more likely as it is becoming
“increasingly challenging” for AGN to pursue inversion as
path to value creation
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Sasha Damouni in New York at +1-212-617-7787 or
sdamouni2@bloomberg.net
To contact the editor responsible for this story:
Brad Skillman at +1-212-617-2763 or
bskillman1@bloomberg.net
2014-06-20 14:21:54.227 GMT
By Sasha Damouni
June 20 (Bloomberg) -- Pfizer/AstraZeneca deal rationale
still seen as “strong” with talks that may resume over next
3-6 months, if Astra is willing to engage w/ Pfizer on a
friendly deal, JPMorgan analyst Chris Schott said in note.
* Schott says PFE may pursue other business development
transactions to achieve greater critical mass in operating
segments
* PFE could look at mid-cap biotech acquisition to build
out its innovative business or a generic/brand generic
acquisition to broaden GEP portfolio
* JPM added sees a Valeant-Allergan combination as
“incrementally” more likely as it is becoming
“increasingly challenging” for AGN to pursue inversion as
path to value creation
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Sasha Damouni in New York at +1-212-617-7787 or
sdamouni2@bloomberg.net
To contact the editor responsible for this story:
Brad Skillman at +1-212-617-2763 or
bskillman1@bloomberg.net